Mean (SE) values at first and last doses of treatments for pretreatment % predicted FEV1, % predicted FEV1 1 hour after treatment (pre-challenge), and methacholine PC20 (mg/ml)
| Genotype | BUD + FM | FP + SM | |||||
|---|---|---|---|---|---|---|---|
| First dose | Last dose | 95% CI | First dose | Last dose | 95% CI | ||
| BUD = budesonide; FM = formoterol, FP = fluticasone propionate; SM = salmeterol. | |||||||
| 95% CI values for methacholine PC20 are expressed as doubling dilution difference. | |||||||
| Pretreatment FEV1 | |||||||
| Arg-16 | 82 (3) | 86 (4) | (−14 to 7) | 82 (4) | 86 (5) | (−17 to 9) | |
| Gly-16 | 75 (5) | 81 (5) | (−21 to 8) | 74 (5) | 79 (5) | (−19 to 9) | |
| 95% CI | (−5 to 20) | (−8 to 17) | (−5 to 22) | (−7 to 21) | |||
| FEV1 1 hour after treatment (pre-challenge) | |||||||
| Arg-16 | 90 (4) | 92 (4) | (−14 to 9) | 89 (4) | 90 (4) | (−14 to 11) | |
| Gly-16 | 86 (5) | 87 (5) | (−14 to 14) | 81 (5) | 83 (4) | (−16 to 12) | |
| 95% CI | (−9 to 16) | (−8 to 18) | (−6 to 23) | (−5 to 20) | |||
| Methacholine PC20 | |||||||
| Arg-16 | 12.2 (2.9) | 9.1 (2.6) | (−0.7 to 1.5) | 6.2 (2.5) | 4.1 (1.6) | (−1.0 to 2.2) | |
| Gly-16 | 13.2 (4.2) | 11.8 (2.4) | (−1.0 to 1.3) | 10.7 (3.1) | 6.4 (2.3) | (−0.6 to 2.1) | |
| 95% CI | (−1.3 to 1.1) | (−1.5 to 0.7) | (−2.2 to 0.7) | (−2.2 to 0.9) | |||